Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments

Immunotherapy is changing the paradigm of multiple myeloma (MM) management and daratumumab is the first-in-class human monoclonal antibody targeting CD38 approved for the treatment of this malignancy. Daratumumab exerts anti-myeloma activity by different mechanisms of action as antibody-dependent ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Offidani, Massimo, Corvatta, Laura, Morè, Sonia, Nappi, Davide, Martinelli, Giovanni, Olivieri, Attilio, Cerchione, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928404/
https://www.ncbi.nlm.nih.gov/pubmed/33680948
http://dx.doi.org/10.3389/fonc.2020.624661

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7928404/
https://www.ncbi.nlm.nih.gov/pubmed/33680948
http://dx.doi.org/10.3389/fonc.2020.624661

Ejemplares similares